Carbonic acid, ethyl isohexyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: Carbonic acid, ethyl isohexyl ester
• 英文别名: ethyl 4-methylpentyl carbonate
• 化学式: C₉H₁₈O₃
• 分子量: 174.24
• InChiKey: VIVOWLACDQNCQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• CONTROLLED RELEASE PREPARATION
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160128945A1

  公开（公告）日：2016-05-12

  A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.

  提供了一种受控释放制剂，其中活性成分的释放受到控制，通过在胃肠道内停留或缓慢迁移来延长时间释放活性成分，采用胶囊化片剂、颗粒或细颗粒的方式，其中活性成分的释放受到控制，并且使用了一种凝胶形成聚合物。所述的片剂、颗粒或细颗粒在含有活性成分的核心颗粒上形成了一个受控释放的涂层。
• Antibacterial compound
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030171330A1

  公开（公告）日：2003-09-11

  A compound of formula (I) 1 wherein R 1 and R 2 represent a hydrogen atom or an aryl, a heterocyclic, an alkyl or an alkenyl, which are optionally substituted, R 3 represents a hydrogen atom or a hydroxyl and X 1 and X 2 represent an oxygen atom, a sulfur atom or a nitrogen containing group, a pharmaceutically acceptable derivative thereof or a salt thereof. A pharmaceutical composition comprising the compound for the prevention or treatment of a bacterial infection. A method for the prevention or treatment of a bacterial infection in a warm-blooded animal comprising administering a pharmacologically effective amount of the compound.

  式（I）的化合物，其中R1和R2代表氢原子或芳基、杂环基、烷基或烯基，可以是可选择取代的；R3代表氢原子或羟基；X1和X2代表氧原子、硫原子或含氮基团，其药用上可接受的衍生物或盐。包括该化合物的药物组合物，用于预防或治疗细菌感染。一种方法，用于在温血动物中预防或治疗细菌感染，包括给予该化合物的药理有效量。
• NOVEL A-500359 DERIVATIVES
  申请人：Sankyo Company, Limited

  公开号：EP1209166A1

  公开（公告）日：2002-05-29

  The present invention relates to a compound of formula (I) (wherein R1 and R2 represent an aryl group, a heterocyclic group, an alkyl group, an alkenyl group and the like which are optionally substituted, R3 represents a hydrogen atom or a hydroxyl group, and X1 and X2 represent an oxygen atom or a sulfur atom, or a nitrogen atom which may be substituted), a pharmaceutically acceptable derivative thereof or a salt thereof. The present invention also relates to a pharmaceutical composition comprising a compound described above as an active ingredient for the prevention or treatment of bacterial infections. The present invention includes the use of a compound described above in order to prepare a medicament effective in the prevention or treatment of bacterial infections. The present invention is concerned with a method for the prevention or treatment of bacterial infections in warm-blooded animals comprising administering a pharmacologically effective amount of a compound described above to them.

  本发明涉及一种式(I)化合物（其中 R1 和 R2 代表芳基、杂环基、烷基、烯基等任选被取代的基团，R3 代表氢原子或羟基，X1 和 X2 代表氧原子或硫原子或可被取代的氮原子）、其药学上可接受的衍生物或其盐。 本发明还涉及一种药物组合物，其中包含上述化合物作为活性成分，用于预防或治疗细菌感染。 本发明包括使用上述化合物制备有效预防或治疗细菌感染的药物。 本发明涉及一种预防或治疗温血动物细菌感染的方法，包括给温血动物服用药理有效量的上述化合物。
• NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20150056165A1

  公开（公告）日：2015-02-26

  The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
• US7157442B2
  申请人：——

  公开号：US7157442B2

  公开（公告）日：2007-01-02